Volume : 09, Issue : 08, August – 2022
Title:
18.A PROSPECTIVE OBSERVATIONAL STUDY ON DRUG- DRUG INTERACTIONS IN CARDIAC PATIENTS AT A TERTIARY CARE HOSPITAL
Authors :
Md.Majid Iqbal, Md Inzemam ul Haque, Syeda Mariyam, Uroosa Soha*, Sumaiya Sultana
Abstract :
Aim:To study the occurrence, frequency and severity of significant drug-drug interactions in cardiac patients. Method: This study was carried out for duration of 6 months at the inpatient department of General medicine in Osmania general hospital, Afzalgunj, Hyderabad. The data of 75 patients was collected and the frequently occurring drug-drug interactions among the selected patients were noted.
Results: The study identified various drug-drug interactions in cardiac patients with minor drug interactions being more common (52%). The subjects were distributed on the basis of age, gender, diagnosis and number of drugs used. The cardiovascular drugs prescribed were Anticoagulants (25.7%), Anti hyper lipidemics (21.3%), Diuretics (16.9%) and Calcium channel blockers (13.2%), ACE-inhibitors (9.5%), Vasodilators (6.6%) and Angiotensin receptor blockers (6.6%).
Conclusion: The present study shows that DDI’s are frequent among hospitalized cardiac patients and highlights the need to screen prescriptions of cardiovascular patients for DDI’s, as this helps in detection and prevention of possible adverse drug interactions.Thus, this study assists in understanding the factors associated with DDI’s that can help in safe and effective use of drugs in future.
Key words: Drug-drug interactions, cardiovascular, patients, adverse drug.
Cite This Article:
Please cite this article in press Uroosa Soha et al, A Prospective Observational Study On Drug- Drug Interactions In Cardiac Patients At A Tertiary Care Hospital., Indo Am. J. P. Sci, 2022; 09(8).
,
Number of Downloads : 10
References:
1. Tari L, Anwar S, Liang S, Cai J, Baral C. Discovering drug–drug interactions: a text mining and reasoning approach based on properties of drug metabolism. Bioinformatics. 2010; 26(18):547–53.
2. Polasek TM, Lin FPY, Miners JO, Doogue MP. Perpetrators of pharmacokinetic drug drug interactions arising from altered cytochrome P450 activity: a criteriabased assessment. Br. J Clin Pharmacol. 2011; 71(5):727–36.
3. Kashyap M, Cruz SD, Sachdev A, Tiwari P. Drug-drug interactions and their predictors: results from Indian elderly inpatients. Pharm Pract (Granada). 2013; 11(4):191–5.
4. Hazlet TK, Lee TA, Hansten PD, Horn JR. Performance of community pharmacy drug interaction software. J Am Pharm Assoc (Wash) 2001; 41:200–4.
5. Chrischilles EA, Fulda TR, Byrns PJ, Winckler SC, Rupp MT, Chui MA. The role of pharmacy computer systems in preventing medication errors. J Am Pharm Assoc(Wash) 2002;42:439–48
6. Murtaza G, Khan MYG, Azhar S, Khan SA, Khan TM. Assessment of potential drug drug interactions and its associated factors in the hospitalized cardiac patients. Saudi Pharm J.
7. Mortality and Causes of Death Collaborators. “Global, regional, and national agesex specific all-cause and cause-specific mortality for 240 causes of death, 19902013: a systematic analysis for the Global Burden of Disease Study 2013”. Lancet. 2014; 385 (9963):117–71. 2016; 24:220-5.
8. Shanthi Mendis, Pekka Puska, Bo Norrving. World Health Organization (2011). Global Atlas on Cardiovascular Disease Prevention and Control. World Health
9. Organization in collaboration with the World Heart Federation and the World Stroke Organization. 2014 August;pg.no 3–18
10. Moran, AE; Forouzanfar, MH; Roth, GA; Mensah, GA; Ezzati, M; Murray, CJ; Naghavi, M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study. Circulation. 2014 April; 129 (14):1483-92.
11. GBD 2013 Mortality and Causes of Death Certificates. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990– 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171.
12. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997; 79:115-119.